- Immunosuppressants
- Immunomodulators
Multiple Sclerosis Therapeutics Market size was valued at USD 27,534.2 million in 2022 and is expected to grow at a CAGR of 5.6% from 2023-2029. Multiple sclerosis is a chronic immune-mediated inflammatory disease that disturbs nerve cells in the brain and spinal cord, producing demyelination, neurodegeneration, and axonal transection. muscle relaxants, physical therapy, antidepressants, and injectable, infused, and oral medications are some of the most extensively used therapies. Glatiramer acetate and Interferon-beta are injectable treatments that are provided into the muscle or under the skin, oral medications are teriflunomide, cladribine, and dimethyl fumarate; and intravenous infusion therapies are ocrelizumab, natalizumab, and alemtuzumab. The growing prevalence of multiple sclerosis can lead to the growth of the multiple sclerosis therapeutics markets. Moreover, growing healthcare expenditure which facilitates in refining its infrastructure, and increasing initiatives by private and public organizations to spread awareness are some primary factors that can boost the global multiple sclerosis therapeutics markets. Apart from these, increasing initiatives by private and public organizations to increase awareness, an increase in disposable income, and a surge in the development of advanced interferon, monoclonal antibodies, immunomodulators, and immunosuppressants can also accelerate the market in the future. The growing geriatric population and incessantly changing lifestyles can also drive the global market further. However, some factors such as the high treatment cost of multiple sclerosis and the lack of skilled professionals, and the absence of good healthcare infrastructure in developing nations can restrain the growth of the market. The growing number of research and development events can create an opportunity for the growth of the global multiple sclerosis therapeutics markets.
Multiple Sclerosis Therapeutics Market Key Developments:
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
One of the major reasons for the growth of the global multiple sclerosis therapeutics markets is the substantial research and development investment by key players. Numerous novel molecules are being examined for the cure of multiple sclerosis. Some of the important pharmaceutical companies highlight the development of the disabilities related to multiple sclerosis. The pipeline portfolio of numerous companies comprises agents with diverse mechanisms of action, which is expected to enhance their demand from doctors, directing to alteration of the treatment algorithm in the few years.
The primary factors that drive the market are the growing focus on research and development to innovate novel drugs by chief market players, new launches of products, growing government initiatives to expand the availability of care and treatment, and the increasing prevalence of multiple sclerosis.
Biogen (U.S.), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel), Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation) (New Jersey), and Bristol-Myers Squibb Company (U.S.) are the key players of the market.
North America is dominating the multiple sclerosis therapeutics markets.
Oral placed under the route of administration type segment is the fastest-growing segment of the market.
1. Executive Summary |
2. Global Multiple Sclerosis Therapeutics Market Introduction |
2.1. Global Multiple Sclerosis Therapeutics Market Taxonomy |
2.2. Global Multiple Sclerosis Therapeutics Market Definitions |
2.2.1. Product Type |
2.2.2. Route Of Administration |
2.2.3. By Region |
3. Global Multiple Sclerosis Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Multiple Sclerosis Therapeutics Market Dynamic Factors - Impact Analysis |
3.6. Global Multiple Sclerosis Therapeutics Market Competition Landscape |
3.7. Epidemiology |
4. Global Multiple Sclerosis Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Multiple Sclerosis Therapeutics Market, By Product Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.1. Immunosuppressants |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Immunomodulators |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6. Global Multiple Sclerosis Therapeutics Market, By Route Of Administration, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.1. Oral |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Injectable |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Intravenous |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Multiple Sclerosis Therapeutics Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia-Pacific |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Latin America |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Middle East and Africa |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Global Multiple Sclerosis Therapeutics Market - Opportunity Analysis Index, By Product Type, By Route Of Administration, and Region, 2023 - 2029 |
8. North America Multiple Sclerosis Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
8.1.1. Immunosuppressants |
8.1.2. Immunomodulators |
8.2. Route Of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
8.2.1. Oral |
8.2.2. Injectable |
8.2.3. Intravenous |
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
8.3.1. USA |
8.3.2. Canada |
8.4. North America Multiple Sclerosis Therapeutics Market - Opportunity Analysis Index, By Product Type, By Route Of Administration, and Country, 2023 - 2029 |
8.5. North America Multiple Sclerosis Therapeutics Market Dynamics Trends |
9. Europe Multiple Sclerosis Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
9.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Immunosuppressants |
9.1.2. Immunomodulators |
9.2. Route Of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Oral |
9.2.2. Injectable |
9.2.3. Intravenous |
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Germany |
9.3.2. UK |
9.3.3. France |
9.3.4. Spain |
9.3.5. Italy |
9.3.6. Rest of Europe |
9.4. Europe Multiple Sclerosis Therapeutics Market - Opportunity Analysis Index, By Product Type, By Route Of Administration, and Country, 2023 - 2029 |
9.5. Europe Multiple Sclerosis Therapeutics Market Dynamics Trends |
10. Asia-Pacific Multiple Sclerosis Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
10.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Immunosuppressants |
10.1.2. Immunomodulators |
10.2. Route Of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Oral |
10.2.2. Injectable |
10.2.3. Intravenous |
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.3.1. China |
10.3.2. India |
10.3.3. Japan |
10.3.4. ASEAN |
10.3.5. Australia & New Zealand |
10.3.6. Rest of Asia-Pacific |
10.4. Asia-Pacific Multiple Sclerosis Therapeutics Market - Opportunity Analysis Index, By Product Type, By Route Of Administration, and Country, 2023 - 2029 |
10.5. Asia-Pacific Multiple Sclerosis Therapeutics Market Dynamics Trends |
11. Latin America Multiple Sclerosis Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
11.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Immunosuppressants |
11.1.2. Immunomodulators |
11.2. Route Of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Oral |
11.2.2. Injectable |
11.2.3. Intravenous |
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Brazil |
11.3.2. Mexico |
11.3.3. Rest of Latin America |
11.4. Latin America Multiple Sclerosis Therapeutics Market - Opportunity Analysis Index, By Product Type, By Route Of Administration, and Country, 2023 - 2029 |
11.5. Latin America Multiple Sclerosis Therapeutics Market Dynamics Trends |
12. Middle East and Africa Multiple Sclerosis Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
12.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Immunosuppressants |
12.1.2. Immunomodulators |
12.2. Route Of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Oral |
12.2.2. Injectable |
12.2.3. Intravenous |
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Gulf Cooperation Council (GCC) Countries |
12.3.2. South Africa |
12.3.3. Rest of MEA |
12.4. MEA Multiple Sclerosis Therapeutics Market- Opportunity Analysis Index, By Product Type, By Route Of Administration, and Country, 2023 - 2029 |
12.5. MEA Multiple Sclerosis Therapeutics Market Dynamics Trends |
13. Competition Landscape |
13.1. Strategic Dashboard of Top Market Players |
13.2. Company Profiles (Introduction, Financial Analysis, Key Product Types, Key Developments, Strategies, and SWOT Analysis) |
13.2.1. Biogen (U.S.) |
13.2.2. Pfizer Inc. (U.S.) |
13.2.3. F. Hoffmann-La Roche Ltd. (Switzerland) |
13.2.4. Novartis AG (Switzerland) |
13.2.5. Merck & Co., Inc. (U.S.) |
13.2.6. Sanofi (France) |
13.2.7. Teva Pharmaceutical Industries Ltd. (Israel) |
13.2.8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation) (New Jersey) |
13.2.9. Bristol-Myers Squibb Company (U.S.) |
14. Research Methodology |
15. Key Assumptions and Acronyms |